STELIC Institute and Co., a Tokyo based bioventure company specializing in regenerative medicine has developed a new treatment method for acute liner failure. The company’s stem cell dynamicm research team has shown that a protein called chemoking 1 CXCL102 directly affects hepatic cells, regulating their replication and proliferation. Research results demonstrated for the first time that hepatic cells possess a mechanism for attempting to repair the wide ranging hepatic cell necrosis associated with drug induced acute liner failure, and that –CXCL10 antibodies strengthen this type of self repairing function at the in vivo level.

Source: Bio Spectrum Biospectrumasia.com Jan-Feb 2007. Vol 2 Issue 1.